Reprogramming the Genome: Crispr-Cas-Based Human Disease Therapy, 181
暫譯: 基因組重編程:基於CRISPR-Cas的人類疾病療法

Singh, Vijai

  • 出版商: Academic Press
  • 出版日期: 2021-06-15
  • 售價: $6,190
  • 貴賓價: 9.5$5,881
  • 語言: 英文
  • 頁數: 394
  • 裝訂: Hardcover - also called cloth, retail trade, or trade
  • ISBN: 0323853234
  • ISBN-13: 9780323853231
  • 海外代購書籍(需單獨結帳)

商品描述

Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy, presents the collation of chapters written by eminent scientists worldwide. CRISPR-Cas9 is a key technology for targeted genome editing and regulation in a number of organisms including mammalian cells. It is a rapid, simple, and cost-effective solution. CRISPR-Cas system has recently gained much scientific and public attention. This volume covers CRISPR-Cas9 based mammalian genome editing, creating disease models, cancer therapy, neurological, heredity, blood disorders, defective gene correction, stem cells therapy, epigenetic modifications, patents, ethics, biosafety and regulatory issues challenges and opportunities. This book is a key source of information on mammalian genome editing available in a single volume. This book will be useful for beginners in mammalian genome editing and also students, researchers, scientists, policymakers, clinicians and stakeholders interested in genome editing in several areas.

商品描述(中文翻譯)

《重新編程基因組:基於CRISPR-Cas的人類疾病療法》匯集了全球著名科學家撰寫的章節。CRISPR-Cas9是一項關鍵技術,用於多種生物體(包括哺乳動物細胞)的目標基因組編輯和調控。這是一種快速、簡單且具成本效益的解決方案。CRISPR-Cas系統最近獲得了大量的科學和公眾關注。本書涵蓋了基於CRISPR-Cas9的哺乳動物基因組編輯、疾病模型的創建、癌症療法、神經學、遺傳、血液疾病、缺陷基因修正、幹細胞療法、表觀遺傳修飾、專利、倫理、生物安全及監管問題的挑戰與機會。本書是有關哺乳動物基因組編輯的關鍵資訊來源,集中於單一卷冊中。這本書對於哺乳動物基因組編輯的初學者以及對基因組編輯感興趣的學生、研究人員、科學家、政策制定者、臨床醫生和相關利益者都將非常有用。